Conditions: Opioid-Related Disorders
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 44
Healthy volunteers: yes

Brief summary:
To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent, recreational opioid users.

Detailed description:

Arms:
arm 1: Placebo powder snorted with all other arms taken crossover therafter arm 2: Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter arm 3: Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter arm 4: Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter arm 5: Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter

Interventions: intervention 1: Placebo taken first intervention 2: Generic H/A taken first intervention 3: Vycavert taken first intervention 4: Generic H/A plus i taken first intervention 5: Generic H/A plus p taken first
Intervention descriptions: intervention 1: Snorted in both nostrils within 5 minutes; 48 hours washout between doses intervention 2: Snorted in both nostrils within 5 minutes; 48 hours washout between doses intervention 3: Snorted in both nostrils within 5 minutes; 48 hours washout between doses intervention 4: Snorted in both nostrils within 5 minutes; 48 hours washout between doses intervention 5: Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Protocol document: